A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment

Fujio, Kozo; Watanabe, Masami; Ueki, Hideo; Li, Shun Ai; Kinoshita, Rie; Ochiai, Kazuhiko; Futami, Junichiro; Watanabe, Tetsu; Nasu, Yasutomo; Kumon, Hiromi

doi:10.3892/or.2015.3770

Cited by 14 publications

(7 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In an in vivo study, simultaneous intraperitoneal administration of PAP-fused IL-7, GMCSF, IL-2, and IL-4 resulted in a decreased induction and growth in PAP expressing tumors. This finding suggests that IL-7 in addition to these other cytokines has an antitumor role in prostate cancer (44). The CD47 gene is over expressed in several tumors including glioblastomas.…”

Section: Potential Anti-tumor Effects Of Il-7mentioning

confidence: 79%

The role of IL-7 in Immunity and Cancer

2017

View full text Add to dashboard Cite

Abstract. Interleukin-7 (IL-7) is a cytokine that has been known since long in immunology, mainly regarding its effects on T-cells and B-cells. IL-7 has been demonstrated to be necessary for both B-cell and T-cell proliferation and lack of IL-7 causes immature immune cell arrest. Interestingly, in recent years, certain studies have strongly suggested that the role of IL-7 is far beyond the field of immunology, it might have direct or indirect effect on cancer. This review aims to summarize the role of IL-7 in immunity and its role in the pathogenesis of neoplasia.

show abstract

Section: Potential Anti-tumor Effects Of Il-7mentioning

confidence: 79%

The role of IL-7 in Immunity and Cancer

2017

View full text Add to dashboard Cite

show abstract

“…It is a secretory prostate-specific protein consisting of 354 amino acids. Over 95% of PCa tissues exerted elevated expression of PAP [ 31 ]. PARM1 codes for a 298-amino acid protein.…”

Section: Discussionmentioning

confidence: 99%

Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens

et al. 2021

View full text Add to dashboard Cite

Prostate cancer is a prevalent cancer in men and consists of both indolent and aggressive phenotypes. While active surveillance is recommended for the former, current treatments for the latter include surgery, radiation, chemo and hormonal therapy. It has been observed that the recurrence in the treated patients is high and results in castration resistant prostate cancer for which treatment options are limited. This scenario has prompted us to consider immunotherapy with synthetic DNA vaccines, as this approach can generate antigen-specific tumor-killing immune cells. Given the multifocal and heterogeneous nature of prostate cancer, we hypothesized that synthetic DNA vaccines targeting different prostate specific antigens are likely to induce broader and improved immunity who are at high risk as well as advanced clinical stage of prostate cancer, compared to a single antigen approach. Utilizing a bioinformatics approach, synthetic enhanced DNA vaccine (SEV) constructs were generated against STEAP1, PAP, PARM1, PSCA, PCTA and PSP94. Synthetic enhanced vaccines for prostate cancer antigens were shown to elicit antigen-specific immune responses in mice and the anti-tumor activity was evident in a prostate tumor challenge mouse model. These studies support further evaluation of the DNA tools for immunotherapy of prostate cancer and perhaps other cancers.

show abstract

“…The use of multiple PAP-fused cytokines (human/mouse GM-CSF, IL-2, IL-4, IL-7) represents a new strategy for vaccines efficacy to be enhanced [37].…”

Section: Sipuleucel-t and Pap-targeted Vaccinesmentioning

confidence: 99%

Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities

Maiorano¹,

Schinzari²,

Ciardiello³

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: In the last years, many new treatment options have widened the therapeutic scenario of genitourinary malignancies. Immunotherapy has shown efficacy, especially in the urothelial and renal cell carcinomas, with no particular relevance in prostate cancer. However, despite the use of immune checkpoint inhibitors, there is still high morbidity and mortality among these neo-plasms. Cancer vaccines represent another way to activate the immune system. We sought to summarize the most recent advances in vaccine therapy for genitourinary malignancies with this review. Methods: We searched Pubmed, Embase and Cochrane Database for clinical trials conducted in the last ten years, focusing on cancer vaccines in the prostate, urothelial and renal cancer. Results: Various therapeutic vaccines, including DNA-based, RNA-based, peptide-based, dendritic cells, viral vectors, and modified tumor cells, have been demonstrated to induce specific immune responses in a variable percentage of patients. However, these responses rarely corresponded to significant survival improvements. Conclusions: Further pre-clinical and clinical studies will improve the knowledge about cancer vaccines in genitourinary malignancies to optimize dosage, select targets with a driver role for tumor development and growth, and finally overcome resistance mechanisms. Combination strategies represent possibly more effective and long-lasting treatments.

show abstract

A vaccine strategy with multiple prostatic acid phosphatase-fused cytokines for prostate cancer treatment

Cited by 14 publications

References 33 publications

The role of IL-7 in Immunity and Cancer

The role of IL-7 in Immunity and Cancer

Immunotherapy of prostate cancer using novel synthetic DNA vaccines targeting multiple tumor antigens

Cancer Vaccines for Genitourinary Tumors: Recent Progresses and Future Possibilities

Contact Info

Product

Resources

About